CADL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -7.75%, SMA50 -10.34%, SMA200 -7.57%). The stock’s 14-day RSI is 41.21 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.08% below its high and over 21.18% above its low. Average 10-day trading volume of 1.15 million shares is below the 3-month average of 1.86 million, indicating normal recent market interest.

Candel Therapeutics, Inc. has 73.27 million shares outstanding. The public float is 56.81 million shares, elevated short interest at 23.04% of float. This equals 12.96 million shares. The short ratio is 6.28 days. Institutional investors hold 71.2% of the float. Insiders own 15.53%. Manning Paul B holds 2.76 million shares, Aguilar-Cordova Estuardo has 919.46 thousand shares and Tak Paul Peter has 225.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.45 thousand shares across 2 transactions.

Candel Therapeutics, Inc. generated EPS of -$0.56 over the past year. Five-year average earnings growth is -43.86%. Wall Street analysts project EPS growth of 34.45% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.24. Next year's EPS is expected at $2.69. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $7.00. The high target offers 145.75% upside. The low target suggests -33.84% downside. The mean target is $18.50. This offers 74.86% upside. Candel Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -52.68%. The prior quarter beat by 125.0%. Over the last six quarters, Apple has recorded several small beats. These include 73.91% in March 13, 2025.

Candel Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.22. This means the shares are trading above this model’s fair value.

Candel Therapeutics, Inc. (NASDAQ:CADL) closed at $10.58 USD, gaining $0.12 (1.15%) from the previous close of $10.46. The stock is currently mid-range between its 52-week high and low $4.35 and $11.36. With a market capitalization of about $775.20 million, Candel Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.51). Key stats such as the average daily volume over the past year has been around 1.90 million shares, volume is running light vs its 52-week average. Headquartered in Needham, MA, Candel Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul-Peter Tak, the company employs approximately 55 people and listed since July 27, 2021. Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients.

Candel Therapeutics, Inc. trades at a P/E ratio of -10.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.8 trading at moderately above to book value. The P/FCF stands at -15.9, also below market averages.

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are flat 4.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Candel Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.81, suggesting 58.88% upside. Our AI forecast model points to short-term weakness (-2.17% over two weeks), a medium-term fall (-54.06% over three months), and a longer-term gain (354.63% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Candel Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.17%, with price expected at $10.35 by August 19, 2026, within a range of $9.99 to $10.70 3-Month Outlook: Projected fall of -54.06%, reaching $4.86 by November 03, 2026, with a range of $4.00 to $5.38. 1-Year Outlook: Projected gain of 354.63%, with price at $48.10 by August 05, 2027, within a range of $46.09 to $63.12.